Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381942 | 0.89 | HTT (0.71) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL29062620 | 0.88 | HTT (0.70) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30669370 | 0.85 | HTT (0.67) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1359033 | 0.85 | HTT (0.50) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30669327 | 0.85 | HTT (0.67) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL12949756 | 0.84 | SMN1; SMN2 (0.71) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL23969816 | 0.83 | HTT (0.67) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1357175 | 0.83 | ALDH1A1 (0.48) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6195550 | 0.82 | HTT (0.47) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL30669399 | 0.82 | HTT (0.67) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021457-B1 | METHOD FOR THE SITE SPECIFIC SYNTHESIS OF NOVEL 3-HYDROXYPYRIDIN-4(1H)-ONES DERIVATIVES FROM AMINOITOLS, PRODUCTS OBTAINED BY THIS METHOD AND THEIR APPLICATIONS | ISTITUTO BIOCHIMICO PAVESE PHA (IT) | 2003-04-09 | — | — | EP | claimed |
| US-6177409-B1 | 2-(ALKYL OR HALOALKYL)-3-HYDROXY PYRAN-4-ONE IS HYDROXYL-PROTECTED, AND REACTED WITH AN AMINO ITOL TO SUBSTITUTED THE INTRACYCLIC OXYGEN OF PYRANONE WITH THE AMINE OF THE AMINO ITOL; IRON(III) CHELATORS FOR BLOOD DISORDERS | INSTITUTO BIOCHIMICO PAVESE PHARMA S.P.A. (IT) | 2001-01-23 | — | — | US | claimed |
| US-20110200536-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE HEALTHCARE AS (NO) | 2011-08-18 | — | — | US | disclosed |
| EP-2178862-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE Healthcare AS (NO) | 2010-04-28 | — | — | EP | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| WO-2009021948-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE HEALTHCARE AS (NO) | 2009-02-19 | — | — | WO | disclosed |
| EP-1021457-B1 | METHOD FOR THE SITE SPECIFIC SYNTHESIS OF NOVEL 3-HYDROXYPYRIDIN-4(1H)-ONES DERIVATIVES FROM AMINOITOLS, PRODUCTS OBTAINED BY THIS METHOD AND THEIR APPLICATIONS | ISTITUTO BIOCHIMICO PAVESE PHA (IT) | 2003-04-09 | — | — | EP | disclosed |
| US-6177409-B1 | 2-(ALKYL OR HALOALKYL)-3-HYDROXY PYRAN-4-ONE IS HYDROXYL-PROTECTED, AND REACTED WITH AN AMINO ITOL TO SUBSTITUTED THE INTRACYCLIC OXYGEN OF PYRANONE WITH THE AMINE OF THE AMINO ITOL; IRON(III) CHELATORS FOR BLOOD DISORDERS | INSTITUTO BIOCHIMICO PAVESE PHARMA S.P.A. (IT) | 2001-01-23 | — | — | US | disclosed |
| EP-1021457-A1 | METHOD FOR THE SITE SPECIFIC SYNTHESIS OF NOVEL 3-HYDROXYPYRIDIN-4(1H)-ONS DERIVATIVES FROM AMINOMONOSACCHARIDES OR AMINOITOLS, PRODUCTS OBTAINED BY THIS METHOD AND THEIR APPLICATIONS | Istituto Biochimico Pavese Pharma SPA (IT) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998001458-A1 | METHOD FOR THE SITE SPECIFIC SYNTHESIS OF NOVEL 3-HYDROXYPYRIDIN-4(1H)-ONS DERIVATIVES FROM AMINOMONOSACCHARIDES OR AMINOITOLS, PRODUCTS OBTAINED BY THIS METHOD AND THEIR APPLICATIONS | ISTITUTO BIOCHIMICO PAVESE PHARMA SPA (IT) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200536-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | TSPO, PML, AIP | HTT 410/4885SMN1; SMN2 2492/4885MEN1 575/4885 |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | PNPO, PGD, PDXK | HTT 4051/4885SMN1; SMN2 2855/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.